Morepen Laboratories Q3 FY25 results (Oct–Dec 2024) and concall

Morepen Labs reported a quarter of modest revenue growth but strong profitability improvement over the nine-month period, driven by a focus on higher-margin products and export markets, particularly Europe. The medical devices segment continued its robust growth, while the API business faced temporary margin pressures from raw material price increases not yet passed on to customers. The company is actively expanding capacity and launching new products, with a long-term vision for sustained growth.